Circulation: Heart Failure is a journal of the American Heart Association. Editor-in-Chief: Nancy Sweitzer, MD, PhD. RT/follows do not imply endorsement.
Joined February 2017
- Tweets 2,651
- Following 476
- Followers 7,959
- Likes 1,365
977 Photos and videos
Epicardium-derived fibroblasts drive the fibro-inflammatory response in Pkp2-deficient arrhythmogenic cardiomyopathy #URochesterResearch @MarioDelmar3 @DanielDWHan @Eric66867284 ahajrnls.org/3QcwoCB
2
396
📣2 weeks left to submit your work to #CircHF for expedited consideration for #ESC2026 simultaneous publication #ESCCongress2026
Presenting at @escardio #ESCCongress 2026? Submit your work by June 22 for expedited consideration for simultaneous publication in #CircHF & maximize the visibility and impact of your research. ahajournals.org/esc #cardiotwitter #ESCCongress2026 #ESC2026
428
Presenting at @escardio #ESCCongress 2026? Submit your work by June 22 for expedited consideration for simultaneous publication in #CircHF & maximize the visibility and impact of your research. ahajournals.org/esc #cardiotwitter #ESCCongress2026 #ESC2026
1
557
May 29
Win ratio analyses support primary DIGIT-HF findings and clarify the contribution of clinically relevant outcomes @JBauersachsMD @DrV_Mann @AndreasJ_Rieth ahajrnls.org/4uPMH7x
1
6
522
May 29
New starts of ARNI and MRA, but not SGLT2i or beta-blockers associated with early reductions in PAP in HF patients across the EF spectrum enrolled in GUIDE-HF @AniqueDucharme @shelleyhallmd @MRMHeart1102 @mrchrtfaildoc @akshaydesaimd ahajrnls.org/43oirEV
5
17
1,162
May 29
Short-term temperature fluctuations trigger ADHF admissions, with distinct risks across hemodynamic phenotypes @kob @KitanoMd @shinakito @blackjtaka ahajrnls.org/4vfzNiO
2
5
547
May 21
Hyperventilation and venous pooling as possible mechanisms underlying dyspnea with preload insufficiency #integratedcareinstitute @ClevelandClinic
ahajrnls.org/4docQ7c
4
8
663
May 20
Center variability in accepting 1st good heart donor match explains national racial disparities in donor heart acceptance @mcolvin89 @shannonmdunlay @RyanTedfordMD @SelmaFMohammed @KBreathettMD @IUMedSchool
ahajrnls.org/42Lx056
1
3
559
May 14
Structural racism drives disparities in advanced HF care. New state-of-the-art review in Circ:HF outlines solutions. #HF #Statistics #Access
ahajrnls.org/4nrCUl4
2
291
May 13
Tolerogenic dendritic cells may help sustain pediatric heart transplant tolerance by suppressing alloreactive T-cells via TGF-β
ahajrnls.org/4fqiVBg
4
367
May 13
Bile Acids, Mitochondria, and Myocardial Stiffness: A Shared Mechanism in Fontan Circulation and Metabolic Dysfunction-Associated Steatotic Liver Disease @sasha_opo @RichKrasuskiMD @AshishHShah3 ahajrnls.org/4uGTRKL
1
4
618
May 12
A roadmap for gene therapy in inherited cardiomyopathy: delivery platforms, genome editing, targets, and trials @radhikawal @MGBResearchNews
ahajrnls.org/48RvWjy
2
4
13
2,104
May 12
How trustworthy AI and big data are shaping the future of heart failure care: opportunities and challenges @mamouei @fwasselbergs
ahajrnls.org/433u17X
1
2
6
493
Circ: Heart Failure retweeted
CardioTTRansform baseline characteristics presented at #HeartFailure26! Great work as usual by @MathewMaurer
@escardio
Largest trial in ATTR CM with widespread use of stabilizers and more SGLT2i than other studies.
Comparison with other trials seen in the tagged pictures. We appear to have a cohort more similar to ATTRIBUTE CM in disease severity. HELIOS B still has the healthiest population.
Copublished in @CircHF
10
33
2,303
Circ: Heart Failure retweeted
Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy
CARDIO-TTRansform is fully enrolled, with 1432 randomized participants who were dosed with study drug or placebo. As the largest transthyretin amyloidosis with cardiomyopathy study to date, it will evaluate whether eplontersen improves cardiovascular outcomes in patients receiving locally available standard of care, including TTR stabilizers.
@MasriAhmadMD @CircHF @CircAHA @gcfmd @SJGreene_md @AndrewJSauer
ahajournals.org/doi/10.1161/…
4
11
925
May 11
Simultaneous Publication w/ #HeartFailure26 by Gunnthorsdottir et al in @CircHF:
📝Medication adherence in HF is shaped by routines, diuretic burden, psychosocial needs, and care continuity, not motivation alone.
➡️ahajournals.org/doi/10.1161/… @AHAScience
1
8
15
1,447
Simultaneous Publication w/ #HeartFailure26 by Maurer et al in @CircHF:
📝CARDIO-TTRansform is designed to evaluate whether eplontersen improves cardiovascular outcomes in patients with ATTR-CM
➡️ahajournals.org/doi/10.1161/… @AHAScience
3
4
601
Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction @hbotker @LabBowen ahajrnls.org/42sHiXw
1
4
584
Vasoactive treatment in cardiogenic shock varies widely across CICUs, driven by patient-level factors and institutional practice patterns @TIMIStudyGroup @DrRobRoswell @ICUDocAP @TIMIStudyGroup ahajournals.org/doi/10.1161/…
1
11
17
1,778
Apr 27
Sacubitril/valsartan lowers BP; ANP drives early effects, while bradykinin contributes modestly during chronic HF therapy @adina_turcu
@vumchealth ahajrnls.org/4t50eGL
1
1
3
585